The Pharmacists View on Therapy Learning Objectives Patient Case MB Elotuzumab Background ELOQUENT2 Study Design LenDex Elotuzumab ELOQUENT2 Efficacy ELOQUENT2 Safety Patient Case ID: 719179
Download Presentation The PPT/PDF document "Novel Agents in Multiple Myeloma" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
Novel Agents in Multiple Myeloma The Pharmacist's View on Therapy Slide2
Learning ObjectivesSlide3
Patient Case MBSlide4
ElotuzumabBackgroundSlide5
ELOQUENT-2 Study DesignLen/Dex ±
ElotuzumabSlide6
ELOQUENT-2 EfficacySlide7
ELOQUENT-2 SafetySlide8
Patient Case JPSlide9
Ixazomib Drug InteractionsSlide10
IxazomibSlide11
TOURMALINE-MM1Ixazomib + Len/Dex vs Placebo + Len/DexSlide12
TOURMALINE-MM1EfficacySlide13
TOURMALINE-MM1ToxicitySlide14
Ixazomib Pharmacist PerspectiveSlide15
Other Ixazomib CombinationsSlide16
Patient Case (cont)JPSlide17
DaratumumabSlide18
Daratumumab Combination TherapySlide19
Current and Future Place in TherapySlide20
Therapies in DevelopmentAntibodiesSlide21
Pembrolizumab + Pom/DexSlide22
Pembrolizumab + Pom/Dex Safety and TolerabilitySlide23
Therapies in DevelopmentSlide24
Questions and AnswersSlide25
AbbreviationsSlide26
Abbreviations (cont)Slide27
Abbreviations (cont)Slide28
Abbreviations (cont)